New combo shrinks liver tumors in hard-to-treat colorectal cancer
NCT ID NCT07024537
First seen May 04, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study tested a combination of liver-directed chemotherapy (FOLFOXIRI via hepatic artery infusion) and a targeted drug (fuquintinib) in 44 people with colorectal cancer that spread to the liver and had not responded to at least two prior treatments. The goal was to see how many patients had their liver tumors shrink significantly. This approach aims to control the disease in the liver, not cure it, and patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.